Related references
Note: Only part of the references are listed.Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF
John R. Teerlink et al.
JACC-HEART FAILURE (2020)
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
Adriaan A. Voors et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
John R. Teerlink et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Hemodynamic effects of inotropic drugs in heart failure A network meta-analysis of clinical trials
Ling Long et al.
MEDICINE (2019)
Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results
Peter Nanasi et al.
CURRENT MEDICINAL CHEMISTRY (2018)
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure The ATOMIC-AHF Study
John R. Teerlink et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R. Teerlink et al.
LANCET (2016)
Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine beta-Cardiac Myosin
Yingying Liu et al.
BIOCHEMISTRY (2015)
Use of Inotropic Agents in Treatment of Systolic Heart Failure
Sohaib Tariq et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity
Donald A. Winkelmann et al.
NATURE COMMUNICATIONS (2015)
Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating Genetic Diseases
James A. Spudich
BIOPHYSICAL JOURNAL (2014)
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
John R. Teerlink et al.
LANCET (2011)
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Fady I. Malik et al.
SCIENCE (2011)
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
John R. Teerlink et al.
HEART FAILURE REVIEWS (2009)
Share Paper
